Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomised, double-blind, double-dummy, two-period, cross-over study to determine the PK [pharmacokinetics], PD [pharmacodynamics] and safety of multiple doses of V1512 [melevodopa/carbidopa] effervescent tablets in Parkinson's disease patients compared to Sinemet [levodopa/carbidopa] oral tablets

Trial Profile

Randomised, double-blind, double-dummy, two-period, cross-over study to determine the PK [pharmacokinetics], PD [pharmacodynamics] and safety of multiple doses of V1512 [melevodopa/carbidopa] effervescent tablets in Parkinson's disease patients compared to Sinemet [levodopa/carbidopa] oral tablets

Completed
Phase of Trial: Phase I

Latest Information Update: 22 Jul 2011

At a glance

  • Drugs Melevodopa/carbidopa (Primary) ; Entacapone; Levodopa/carbidopa
  • Indications Parkinson's disease
  • Focus Pharmacokinetics
  • Sponsors Vernalis
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 22 Jul 2011 Actual end date (Nov 2007) added as reported by ClinicalTrials.gov.
    • 22 Jul 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top